Skip to main content
SUPERNUS PHARMACEUTICALS, INC. logo

SUPERNUS PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · SUPN ISIN · US8684591089 LEI · 549300GRM36VBKISYJ58 US Manufacturing
Filings indexed 1,106 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country US United States of America
Listing US SUPN

About SUPERNUS PHARMACEUTICALS, INC.

https://www.supernus.com

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company's portfolio targets a range of neurological and psychiatric conditions, including epilepsy, migraine, Parkinson's disease, and Attention-Deficit/Hyperactivity Disorder (ADHD). Its key commercial products include Qelbree, Gocovri, Oxtellar XR, and Trokendi XR. Supernus focuses on innovation and maintains a pipeline of product candidates to address unmet medical needs within the CNS therapeutic area.

Recent filings

Filing Released Lang Actions
8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)
Regulatory Filings
2026-04-22 English
8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)
Regulatory Filings
2026-04-07 English
SCHEDULE 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)
Major Shareholding Notification
2026-03-27 English
4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)
Director's Dealing
2026-03-18 English
4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)
Director's Dealing
2026-03-03 English
4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)
Director's Dealing
2026-03-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.